Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
51.99
-0.85 (-1.61%)
Nov 13, 2024, 4:00 PM EST - Market closed

Company Description

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.

The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates.

Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Janux Therapeutics, Inc.
Janux Therapeutics logo
Country United States
Founded 2017
IPO Date Jun 11, 2021
Industry Biotechnology
Sector Healthcare
Employees 64
CEO David Campbell

Contact Details

Address:
10955 Vista Sorrento Parkway, Suite 200
San Diego, California 92130
United States
Phone 858 751 4493
Website januxrx.com

Stock Details

Ticker Symbol JANX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $17.00
CIK Code 0001817713
CUSIP Number 47103J105
ISIN Number US47103J1051
Employer ID 82-2289112
SIC Code 2834

Key Executives

Name Position
Dr. David Alan Campbell Ph.D. President, Chief Executive Officer and Director
Charles M. Winter Chief Technical Officer
Byron Robinson J.D., Ph.D. Chief Strategy Officer
Matt Whitmire Vice President of Finance
Maria Dobek Principal Accounting Officer and Vice President of Accounting
Dr. Tommy Diraimondo Ph.D. Chief Scientific Officer
James Pennington General Counsel
Andy Hollman Meyer Chief Business Officer

Latest SEC Filings

Date Type Title
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 6, 2024 10-Q Quarterly Report
Nov 6, 2024 8-K Current Report
Nov 4, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 1, 2024 144 Filing
Nov 1, 2024 144 Filing
Nov 1, 2024 144 Filing
Nov 1, 2024 144 Filing
Nov 1, 2024 144 Filing